Menu Search
Equities

Amphastar Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
29A:MUN

Amphastar Pharmaceuticals Inc

Actions
  • Price (EUR)24.01
  • Today's Change0.00 / 0.00%
  • Shares traded40.00
  • 1 Year change-24.83%
  • Beta0.8557
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

  • Revenue in USD (TTM)723.31m
  • Net income in USD111.63m
  • Incorporated2004
  • Employees2.03k
  • Location
    Amphastar Pharmaceuticals Inc11570 6th StRANCHO CUCAMONGA 91730United StatesUSA
  • Phone+1 (909) 980-9484
  • Fax+1 (302) 655-5049
  • Websitehttps://amphastar.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.